New immunotherapies for cancer and beyond
Chimeric antigen receptor (CAR) T cells are genetically engineered immune cells that destroy target cells with precision thanks to combined antigen binding and T cell activating functions. Their adaptation has enabled new treatments in patients with haematological B cell malignancies. They are very promising for other cancer types and diseases, such as senescence-associated pathologies, but limitations from the antigenic heterogeneity or impaired T cell trafficking must be solved. The EU-funded CARsen project will develop a novel therapeutic concept through the engineering of T cells against senescent cells that will be combined with therapies that induce senescence in tumour cells. The new therapy will be tested for safety and efficacy in murine models of cellular senescence and solid tumours.
Fields of science
Funding SchemeERC-STG - Starting Grant
See on map